Parallel Advisors, LLC Day One Biopharmaceuticals, Inc. Transaction History
Parallel Advisors, LLC
- $4.34 Billion
- Q4 2024
A detailed history of Parallel Advisors, LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 4 shares of DAWN stock, worth $48. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4Holding current value
$48% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
184Shares Held
85.3MCall Options Held
154KPut Options Held
224K-
Ra Capital Management, L.P. Boston, MA7.87MShares$96.1 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$78.5 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$71.4 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$59.5 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$55.4 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $897M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...